Shares of Axsome Therapeutics Inc. AXSM, -0.27% tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd. TEVA, +4.48% is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome’s depression treatment. Axsome’s stock has gained 95.8% over the past year, while the S&P 500 SPX, +0.22% declined 7.6%.
Item 8.01 Other Events.
This article was originally published by Marketwatch.com. Read the original article here.
